insights_auto
Why is CRSP up 3.11%?
Dive Deeperchevron_right
CRSP:NASDAQ
Crispr Therapeutics AG
$50.07
arrow_upward
+3.11%(+1.51) 1D
$49.35
arrow_downward
-1.44% (-0.72)bedtimeAfter hours
Closed: Nov 6, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CRSP...
Open
$48.98
High
$50.27
Low
$48.41
Mkt. cap
4.86B
Avg. vol.
1.46M
Volume
1.24M
52-wk high
$63.45
52-wk low
$44.12
EPS
-$4.75
Beta
1.49
Shares outstanding
97.00M
No. of employees
393
Open
$48.98
High
$50.27
Low
$48.41
Mkt. cap
4.86B
Avg. vol.
1.46M
Volume
1.24M
52-wk high
$63.45
52-wk low
$44.12
EPS
-$4.75
Beta
1.49
Shares outstanding
97.00M
No. of employees
393
News stories
From web sources and news partners
Investing.com Canada
·
15 hours ago
Form 144 CRISPR THERAPEUTICS AG For: 6 November By Investing.com
Investing.com India
·
16 hours ago
Form 4 CRISPR Therapeutics AG: Sivakesava Sakhamuri (Chief Technical Officer) For: 4 November By Investing.com
Profile
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023. Wikipedia
About Crispr Therapeutics AG
CEOSamarth Kulkarni
Employees393
Founded2013
HeadquartersZug, Zug, Switzerland
SectorHealth Care
IndustryBiotechnology
Websitecrisprtx.com